Business Description
Coya Therapeutics is a Houston-based clinical-stage biotech company founded in 2020 that focuses on treatments designed to boost the body's regulatory immune cells, known as Tregs, to fight neurological and inflammatory diseases such as ALS, Alzheimer's, Parkinson's, and frontotemporal dementia. Its most advanced drug candidate, COYA 302, is currently in Phase 2 trials and is being developed in partnership with Dr. Reddy's Laboratories. The company also has several earlier-stage candidates targeting autoimmune, neurodegenerative, and metabolic conditions through a range of biological approaches.
